Abstract
Diabetes remains the single most common cause of peripheral neuropathy in the United States and other developed countries, affecting millions of patients. Neuropathic pain is a frequent complication in this group, affecting over 25 % and substantially impacting quality of life and function, even when other neurological deficits are mild. Advances in our understanding of the pathophysiology of neuropathic pain have enabled rational testing of a wide array of pharmacological agents which have proven effective in treating diabetic painful neuropathy. Concurrent advances in the broader field of pain medicine have fostered the development of both pain specialists and multidisciplinary clinics which are available for more refractory cases. With these therapeutic options, the vast majority of patients with DPN can be successfully treated with appropriate strategies, and can return to normal occupational and social functioning.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
2011 national diabetes fact sheet. America Diabetes Association. 2011.
National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. NIH Publication No. 11-3892 Feb 2011.
Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. BMC Neurol. 2011;11(1):7–17.
Hoffman DL, Sadosky A, Alvir J. Cross-national burden of painful diabetic peripheral neuropathy in Asia, Latin America, and the Middle East. Pain Pract. 2009;9(1):35–42.
Aristidis V, Rayaz AM. Diabetic neuropathy: clinical management. 2nd ed. Humana Press Inc; Totowa, NJ, 2007.
Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. Diabetes Care. 1998;21:855–9.
Gooch C, Podwall D. Diabetic neuropathy: clinical features, etiology and therapy. Curr Neurol Neurosci Rep. 2004;4(1):51–61.
Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort. Neurology. 1993;43:817–24.
Töyry JP, Niskanen LK, Länsimies EA, et al. Autonomic neuropathy predicts the development of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1996;27:1316–8.
Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44:1973–88.
Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev. 2006;11(4):294–329. 36p.
Campbell RK, Duby JJ, Rasmussen KA, et al. Diabetic neuropathy: an intensive review. Am J ealth Syst Pharm. 2004;61:160–73.
Argoff CE, Howard S. Pharmacological treatment of diabetic neuropathic pain. Drugs. 2011;71(5):557–89.
Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 1991;45(1):3–9.
Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326(19):1250–6.
Attal N, Cruccu G, Baron R, European Federation of Neurological Societies, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain. 2010 revision. Eur J Neurol. 2010;17(9):1113.
Gooch C. Neuropathic pain. Merritt’s neurology. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005; p. 545–50.
Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduced painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57(3):505–9.
Raskin P, Donofrio PD, Rosenthal NR, CAPSS-141 Study Group, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology. 2004;63(5):865–73.
Thienel U, Neto W, Schwabe SK, et al. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand. 2004;110(4):221–31.
Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo- controlled study. Pain. 2003;106(1–2):151–8.
Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin. 2004;20 Suppl 2:S21–8.
Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61(6):914–8.
Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care. 1992;15:159–65.
Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin: a multicenter, double-blind, vehicle-controlled study. Arch Intern Med. 1991;151:2225–9.
Tandan R, Lewis GA, Krusinski PB, et al. Topical capsaicin in painful diabetic neuropathy: controlled study with long-term follow-up. Diabetes Care. 1992;15(1):8–14.
Backonja MM, Malam TP, Vanhove GF, Tobias JK, C102/106 Study Group. NGX-4010, a high concentration capsaicin patch, for the treatment of post herpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11(4):600–8.
Hollingshead J, Duhmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2006; 3: CD003726. (class I SR).
Freeman R, Raskin P, Hewitt DJ, et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin. 2007;23:147–61.
Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA. 2005;293(24):3043–52.
Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59:1015–21.
Dubinsky RM, Miyasak J. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74:173–6.
Binder A, Baron R. Utility of transcutaneous electrical nerve stimulation in neurologic pain disorders. Neurology. 2010;74:104–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vidal, Y., Brock, C., Gooch, C.L. (2013). Medical Treatments for Painful Diabetic Neuropathy. In: Lawson, E., Backonja, M. (eds) Painful Diabetic Polyneuropathy. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6299-6_5
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6299-6_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6298-9
Online ISBN: 978-1-4614-6299-6
eBook Packages: MedicineMedicine (R0)